Effects of l-Arginine and l-nitro-arginine methyl ester on recovery of neonatal lamb hearts after cold ischemia Evidence for an important role of endothelial production of nitric oxide by Hiramatsu, Takeshi et al.
Effects of L-arginine 
ester on recovery of 
cold ischemia 
and L-nitro-arginine methyl 
neonatal amb hearts after 
Evidence for an important role of endothelial production of 
nitric oxide 
Myocardial ischemia nd reperfusion results in both ventricular and endothelial dysfunction. We 
have found that the endothelial defect is a reduced vasodilator response to an intraarterial infusion 
of acetylcholine that is likely due to reduced nitric oxide release, and we have hypothesized that 
reduced endothelial nitric oxide production contributes to postischemic ardiac dysfunction. 
However, others report that nitric oxide is deleterious after ischemia. We therefore xamined the 
effects of infusions of L-arginine (3 mmol/L), a precursor of nitric oxide, D-arginine (3 mmol/L), an 
inactive stereoisomer ofL-arginine, L-nitro-arginine methyl ester (1 mmol/L); a competitive inhibitor 
of nitric oxide synthase, and L-nitro-arginine methyl ester (1 mmol/L) plus L-arginine (3 mmol/L) 
versus controls in isolated biood-perfused neonatal lamb hearts having 2 hours of cold cardioplegic 
ischemia. L-nitro-arginine methyl ester was given before reperfusion, and L-arginine and D-arginine 
were infused for the first 20 minutes of postischemic reperfusion. At 30 minutes of reperfusion, by 
comparison with the control group, the L-arginine group showed significantly better ecovery (p < 
0.05) of left ventricular systolic function (maximum developed pressure, developed pressure at V10 
[balloon volume to produce an end-diastolic pressure of 10 mm Hg during baseline measurement], 
positive maximum dP/dt, and dP/dt at V10), diastolic function (negative maximum dP/dt), coronary 
blood flow, and endothelial function assessed by the coronary vascular resistance response to 
acetylcholine. The L-nitro-arginine methyl ester hearts showed a significantly poorer recovery (p < 
0.05) in left ventricular function, coronary blood flow, and endothelial function than the control 
group. These effects of L-nitro-arginine methyl ester were reversed to equal control values by adding 
a 3 mmol/L concentration of L-arginine to L-nitro-arginine methyl ester. There were no significant 
differences in the recovery of any variables between the D-arginine and control groups. These results 
point to an important salutary role for the endothelial production of nitric oxide in cardiac recovery 
after hypothermic ischemia in neonatal lamb hearts. The mechanism of these beneficial effects of 
L-arginine after ischemia nd reperfusion is likely due to enhancement of the endothelial production 
of nitric oxide. (J THORAC CARDIOVASC SURG 1995;109:81-7) 
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P r io r  experiments from our laboratory on hypo- 
thermic ischemia and reperfusion in neonatal lamb 
hearts have shown that (1) myocardia! ischemia nd 
reperfusion results in both ventricular and endothe- 
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lial dysfunction I and (2) the endothelial dysfunction 
is characterized by reduced release of nitric oxide 
after hypothermic ischemia and reperfusion. 2 Re- 
cent investigations have characterized endothelium- 
derived relaxing factor as nitric oxide, 3' 4 which is 
produced from the semiessential amino acid L- 
arginine as it is converted to L-citrulline by nitric 
oxide synthase in endothelial cells. 5' 6 In the vascular 
system, nitric oxide release from endothelial cells 
causes vasorelaxation 7' s but also inhibits platelet 9
and leukocyte aggregation. 1° Moreover, nitric oxide 
is a primary radical species and is inactivated by 
superoxide radicals TM 12; conversely, nitric oxide may 
neutralize superoxide radicals. 13 Despite these po- 
tential benefits, nitric oxide production has been 
shown to be deleterious by some authors, 14 but 
others report that nitric oxide may be beneficial 
after northothermic ischemia and reperfusionJ 5-19 
This study was designed to examine the role of 
endothelial production of nitric oxide after hypo- 
thermic ischemia and reperfusion with L-arginine, a 
nitric oxide precursor, and L-nitro-arginine methyl 
ester (L-NAME), a competitive inhibitor of  nitric 
oxide synthase, in neonatal hearts. 
Materials and methods 
Experimental preparation. An isolated blood-perfused 
heart model, previously described, 1'2 was used to study 40 
hearts from neonatal lambs (2.3 to 5.9 kg, 2 to 7 days old). 
Coronary perfusion was established with a roller pump 
and oxygenator system before isolation of the heart. 
Heparinized fresh homologous blood was used as the 
perfusate. Arterial pH was kept at 7.4 (corrected to 
perfusate temperature). Myocardial temperature was 
monitored by thermal probes and the perfusate was 
controlled at 37 ° C except during the hypothermic phase. 
Coronary perfusion pressure was maintained at 60 mm Hg 
except during the hypothermic and reperfusion phases. A 
latex balloon that contained a pressure transducer was 
placed inside the left ventricle through the apex to mea- 
sure left ventricular function. 
Measurements. Left ventricular function was measured 
during isovolumic ontraction by inflating the intraventric- 
ular balloon as described previously. I' 2 The recovery of 
systolic function was evaluated by measuring the maxi- 
mum developed pressure, positive maximum rate of left 
ventricular pressure rise (alP/dr), peak developed pressure 
at a constant balloon volume (V10), and peak dP/dt at 
V10. V10 was defined as the balloon volume to produce 
an end-diastolic pressure of 10 mm Hg during baseline 
measurement. To assess the diastolic function, we mea- 
sured negative maximum dP/dt and end-diastolic pressure 
at V10. Coronary blood flow (CBF) was assessed by an 
electromagnetic flowmeter, which was connected to the 
venous cannula. Coronary endothelial function was as- 
sessed by the coronary vascular resistance (CVR) re- 
7 1 2 sponse to acetylcholine (10 mol/L) infusion." Maxi- 
mum decrease in CVR during the acetylcholine infusion, 
divided by baseline CVR, was defined as the CVR re- 
sponse. To assess endothelium-independent vasodilator 
capacity, we infused trinitroglycerin (3 x 10 -5 mol/L) in 
the same way and measured the CVR response. Arterial 
and venous blood was collected and myocardial oxygen 
consumption was calculated from the hemoglobin concen- 
tration, the oxygen content, and saturation. 1' 2 
Experimental protocol. Baseline measurements were 
made after a 20-minute equilibrium period. Then the 
perfusate was cooled to 15 ° C. After 10 minutes of cooling 
(myocardial temperature = 15 ° C), coronary perfusion 
was stopped and a 20 ml/kg dose of cardioplegic solution 
was given, followed by topical cooling (myocardial tem- 
perature was kept at 10 ° C). A second dose of 10 ml/kg 
was given after 60 minutes. The cardioplegic solution was 
2.5% dextrose solution with potassium chloride in a 
concentration of 20 mEq/L. Reperfusion was begun with 
the perfusate at room temperature and then rewarmed to 
normothermia over 25 minutes. Mean coronary perfusion 
pressure was maintained at 20 mm Hg for the first 5 
minutes, raised to 40 mm Hg for the second 5 minutes, 
and then kept at 60 mm Hg until the end of the experi- 
ment.a, 2 A high oxygen concentration was used during the 
first 15 minutes of reperfusion. Thereafter the gas was 
changed to a low oxygen concentration. 
Experimental groups. The hearts were divided into five 
groups: (1) In the L-arginine group (n = 8), the nitric 
oxide precursor L-arginine was infused into the arterial 
cannula during the first 20 minutes of reperfusion at a rate 
calculated to achieve a concentration of 3 mmol/L in the 
coronary blood. (2) In the D-arginine group (n = 8), 
D-arginine, an inactive stereoisomer of L-arginine, was 
infused at a concentration of 3 mmol/L in the same 
manner as group L-arginine. (3) In the L-NAME group 
(n = 8), a 1 mmol/L dose of L-NAME, a competitive 
inhibitor of nitric oxide synthase, was given in the oxygen- 
ator to achieve a concentration of 1 mmol/L before 
reperfusion. (4) In the L-arginine+L-NAME group (n = 
8), L-arginine and L-NAME were given in the same way as 
in the L-arginine and L-NAME groups. (5) In the control 
group (n = 8), blood alone was reperfused without 
intervention. In two other no-ischemia groups, continuous 
normothermic perfusion was carried out. A 3 mmol/L 
dose of L-arginine was infused in one group (20 minutes) 
and continuous perfusion without L-arginine was con- 
ducted in the second (n = 8 each). Animals in this study 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Na- 
tional Academy of Sciences and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
in 1985). 
Statistics. All values are expressed as mean + standard 
deviation and are analyzed by a statistical analysis system. 
One-way analysis of variance and repeated-measures two- 
way analysis of variance were used to compare the differ- 
ences in recovery between groups. Data were compared 
by the Student-Newman-Keuls te t if analysis of variance 
indicated significant differences. A p value less than 0.05 
was considered to be significant. 
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Table I. Baseline values and percent recovery of ventricular function 
Group 
Control L-AR G DMRG L-NAME ARG +NAME 
Heart rate (beats/rain) 198 -+ 19 212 -+ 19 213 -+ 17 217 _+ 14 220 + i1 
DP (max) 
Baseline (ram Hg) 125 -+ 14 133 + 11 131 _+ 16 135 _+ 19 143 ± 9 
Percent recovery 75.5 -+ 8.0 94.5 -+ 3.4* 79.4 _+ 4.7 66.4 _+ 4.7* 79.6 + 3.6 
DP (V10) 
Baseline (mm Hg) 118 _+ 17 129 - 11 121 -+ 16 124 _+ 19 130 _+ 12 
Percent recovery 75.1 -+ 8.0 90.3 + 5.3* 80.8 _+ 4.1 66.1 _+ 10.1" 80.4 -+ 5.5 
dP/dt (max) 
Baseline (mm Hg/sec) 1910 -+ 311 2034 ,+ 208 1927 _+ 415 2079 _+ 399 2160 + 234 
Percent recovery 68.3 .+ 8.8 88.8 _+ 3.8* 70.8 _+ 7.5 54.9 -+ 10.5" 69.4 + 3.8 
dP/dt (V10) 
Baseline (ram Hg/sec) 1765 ,+ 352 1910 ,+ 249 1740 _+ 415 1890 _+ 315 1944 + 342 
Percent recovery 66.8 + 11.2 87.5 ,+ 4.9* 73.1 _+ 7.4 55.5 -+ 10.7" 71.1 -+ 7.9 
-dP/dt  (max) 
Baseline (mm Hg/sec) 1325 _+ 125 1432 _+ 145 1370 _+ 228 1480 -+ 280 1530 -+ 170 
Percent recovery 60.7 _+ 6.8 74.1 .+ 9.5* 62.6 -+ 9.3 46.4 + 11.1" 59.6 ,+ .0 
EDP (VI0) 
Percent baseline 92.5 .+ 17.1 76.3 .+ 21.2]" 113.8 _+ 46.4 126.9 _+ 52.6 90.0 .+ 21.2 
DP (max), Maximum peak developed pressure; DP (VIO), peak developed pressure at a "constant balloon volume (V1O); dP/dt (max), maximum of peak 
positive LV dP/dt; dP/dt (VIO), LV dP/dt at V10; VIO, volume to produce an end-diastolic pressure of 10 mm Hg during preischemic period; -dP/dt (max), 
maximum of peak negative LV dP/dt; EDP (VIO), end-diastolic pressure at VI0; L-ARG, L-arginine; D-ARG, D-arginine; L-NAME, L-nitro-arginine methyl 
ester. Data are mean -+ standard deviation. 
*p < 0.05 versus control. 
tP < 0.05 versus L-NAME group. 
Table II. Baseline values and percent recovery of coronary blood flow 
Group 
Control L-AR G D-AR G L-NAME AR G +NAME 
Baseline (ml/100 gin) 
Percent baseline 
At 5 min reperfusion 
At 10 rain reperfusion 
At 15 rain reperfusion 
At 20 rain repeffusion 
At 25 rain reperfusion 
At 30 rain reperfusion 
261 -- 43 248 + 34 31l + 55 309 --- 44 275 -+ 109 
21.3 _+ 14.8 38.4 --+ 32.8 22.2 + 5.9 9.2 -+ 6.2 19.6 -+ 10.1 
67.4 + 28.3 110.1 + 48.4* 61.8 + 13.1 38.3 -+ 11.9 49.7 _+ 17.3 
113.6 -+ 29.2 201.2 -+ 28.0* 129.9 -+ 18.8 83.4 -+ 14.5" 123.0 _+ 22.4 
119.4 -+ 34.4 212.2 -+ 38.4* 143.8 -+ 18.2 77.3 -+ 18.4" 118.0 _+ 12.7 
122.2 _+ 34.5 209.4 -+ 42.2* 139.0 -- 15.5 84.6 -+ 24.9* 111.3 _+ 12.6 
133.0 -+ 31.6 203.2 + 32.1" 140.0 -+ 16.8 86.0 -+ 22.6* 120.7 -+ 19.9 
Data are mean -+ standard deviation. L-ARG, L-arginine; D-ARG, D-arginine; L-NAME, L-nitro-arginine methyl ester. 
*p < 0.05 versus control group. 
Results 
Baseline measurements (Tables I to IV). There 
was no significant difference in baseline data among 
the five groups. 
Left ventricular function (Table I). Compared 
with the control group, L-Arginine-treated hearts 
had significantly greater ecovery of all left ventric- 
ular systolic function indices (including maximum 
developed pressure, positive maximum dP/dt, devel- 
oped pressure at V10, and dP/dt at V10) and 
negative maximum dP/dt at 30 minutes of reperfu- 
sion (p < 0.05). Conversely, L-NAME-treated 
hearts showed significantly reduced recovery of all 
systolic function indices and negative maximum 
dP/dt compared with the control group (19 < 0.05). 
The L-arginine hearts showed significantly better 
recovery of end-diastolic pressure at V10 than the 
L-NAME hearts (p < 0.05). The recovery in the 
o-arginine and L-arginine + L-NAME groups was not 
significantly different from that in the control group. 
CBF (Table II). The L-arginine group had signif- 
icantly higher CBF than the control group from 10 
minutes of reperfusion (p < 0.05). The L-NAME 
group had significantly lower CBF than the control 
group from 15 minutes of reperfusion (p < 0.05). 
The recovery in the D-arginine and L-arginine+ 
8 4 Hiramatsu et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1995 
Table III. Baseline values and percent baseline of myocardial oxygen consumption 
Group 
Control L-ARG D-ARG L-NAME ARG +NAME 
Baseline (10 -4 ml/gm) 3.31 + 0.70 4.16 _ 0.64 4.18 ± 1.13 4.41 ± 1.37 4.55 ± 1.00 
Percent baseline 
At 5 min reperfusion 44.5 ± 29.4 46.6 ± 24.7 48.9 + 22.2 18.6 ± 4.1 45.0 --- 33.3 
At 15 rain reperfusion 85.0 - 26.5 104.2 +_ 30.3* 84.8 ± 28.3 62.3 ± 17.0 96.1 - 9.1 
At 20 rain reperfusion 87.6 --- 15.3 111.8 _+ 27.1" 74.5 - 20.3 51.7 _+5.0* 69.1 +- 20.7 
At 30 rain reperfusion 76.1 +- 22.1 96.8 ± 17.6t 78.1 --- 22.0 63.0 ± 8.8 74.4 +- 13.3 
Data are mean +- standard deviation. L-ARG, L-arginine; D-A~RG~ D-arginine; L.NAME, L-nitro-arginine methyl ester. 
*p < 0.05 versus control group. 
tp < 0.05 versus L-NAME group. 
Table IV. Baseline values and percent ecovery of coronary endothelial function 
Group 
Control L-ARG D-ARG L-NAME ARG +NAME 
Baseline CVRR by ACh (%) 
Percent recovery of CVRR to ACh 
Baseline CVRR by TNG (%) 
Percent recovery of CVRR to TNG 
13.5 +- 5.9 14.1 ± 5.6 14.2 _+ 3.5 13.1 ± 3.0 13.6 ± 5.1 
39.2 ± 13.9 61.0 ± 14.8" 40,1 ±_ 10.8 14.1 ± 5.3* 29.0 +_ 8.8 
14.9 +- 2.4 15.0 ± 4.7 15.7 ± 3.1 14.9 _+ 2.8 14.1 _+ 3.0 
42.4 _+ 15.6 36.4 ± 15.4 38,2 -- 7.3 50.7 ± 14.3 42.1 ± 22.4 
Data are mean _+ standard deviation. CVRR, Coronary vascular resistance response; ACh, acetylcholine; TNG, trinitroglycerin; L-ARG, L-arginine; D-ARG, 
o-arginine; L-NAME, L-nitro-arginine methyl ester. 
*p < 0.05 versus control group. 
L-NAME groups was not significantly different from 
that in the control group. There was no significant 
intergroup difference in heart rate at any time (data 
not shown). 
Myocardial oxygen consumption (Table III). At 
15 and 20 minutes of reperfusion, the L-arginine 
hearts had significantly higher myocardial oxygen 
consumption than the control group (p < 0.05). The 
L-NAME group demonstrated significantly reduced 
myocardial oxygen consumption compared with the 
control group at 20 minutes of reperfusion (p < 
0.05) and compared with the L-arginine group at 30 
minutes of reperfusion (p < 0.05). The values in the 
D-arginine and L-arginine+L-NAME groups were 
not significantly different from that in the control 
group. 
Coronary endothelial function (CVR response) 
(Table IV). Recovery of CVR response to acetyl- 
choline at 30 minutes of reperfusion was signifi- 
cantly better in the L-arginine group than in the 
control group (p < 0.05). The L-NAME group 
showed significantly reduced CVR response to ace- 
tylcholine compared with the control group (p < 
0.05). However, all five groups had the same degree 
of recovery of CVR response to trinitroglycerin 
infusion at 30 minutes of repeffusion. 
Effects of L-arginine at normothermia without 
ischemia. To assess the effect of L-arginine at nor- 
mothermia without ischemia, we infused a 3 mmol/L 
dose of L-arginine for 20 minutes in the same 
isolated heart model and examined the change of 
CBF, left ventricular function, and CVR response to 
acetylcholine 10 minutes later. The percent baseline 
of CBF was 121.3% _ 13.6% in L-arginine hearts 
and 112.2% _ 14.1% in control hearts, and there 
was no significant difference between the two 
groups. As for left ventricular function, the percent 
of baseline for maximum developed pressure and 
positive dP/dt was 96.8% _ 4.8% and 96.7% +__ 
5.7%, respectively, in the L-arginine group and 
92.5% _+ 3.3% and 92.8% - 3.5%, respectively, in
the control group. There were no significant differ- 
ences between the two groups in the left ventricular 
functional indices. The percent baseline of CVR 
response to acetylcholine was 73.1% ___ 24% in the 
L-arginine group and 70.5% _ 18.3% in the control 
group, and there was no significant intergroup dif- 
ference. 
Discussion 
The present study demonstrates that infusion of 
L-arginine, but not D-arginine, during early reperfu- 
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sion improved the recovery of systolic and diastolic 
left ventricular function, CBF, myocardial oxygen 
consumption, and endothelial function of neonatal 
lamb hearts after 2 hours of hypothermic cardiople- 
gic ischemia. L-NAME reduced recovery of left 
ventricular function, CBF, and endothelial function, 
and these effects of L-NAME were reversed to equal 
control values by adding L-arginine to L-NAME. 
These results trongly suggest that administration f 
L-arginine during reperfusion may be a useful ther- 
apeutic maneuver. 
The exact mechanism by which L-arginine has a 
beneficial effect remains speculative, but it seems 
quite likely to involve nitric oxide production. One 
possible mechanism would be through increased 
coronary blood flow, 7' 8 assuming that endothelial 
nitric oxide release is increased by supplying more 
substrate for nitric oxide production (L-arginine) 
during reperfusion. The significantly higher levels of 
CBF after ischemia in the L-arginine group and the 
significantly reduced postischemic CBF in the L- 
NAME group would support this hypothesis. Our 
laboratory has previously found that administration 
of trinitroglycerin (which likely works through a 
nitric oxide mechanism) would offset he deleterious 
effects of high-pressure perfusion. 2° We also have 
found that trinitroglycerin provided a better ecov- 
ery of mechanical function in the postischemic pe- 
riod after cold cardioplegic schemia. 21 Increases in 
CBF may potentially lead to improved ventricular 
function through the Gregg or "garden hose" f- 
fect. 22 However, recent experiments from our labo- 
ratory have shown that postischemic infusion of 
theophylline (an adenosine receptor antagonist) 
caused increased CBF and lowered CVR but was 
associated with worse recovery of ventricular func- 
tion. 23 Therefore, coronary vasodilation during 
reperfusion is not always associated with improved 
recovery of contractile function after hypothermic 
ischemia. Moreover, the results of the infusion of a 
3 mmol/L concentration f L-arginine at normother- 
mia suggest hat in our isolated heart model, L- 
arginine itself does not induce significant coronary 
vasodilation at normothermia without ischemia. It is 
clearly possible that the beneficial vasodilatory effect 
of L-arginine is particularly important only after 
ischemia nd reperfusion. 
A number of recent studies are pertinent to the 
current study and support its conclusions. Normo- 
thermic ischemia nd reperfusion have been shown 
to result in diminished nitric oxide release from 
endothelial cells, z4 and attempts have been made to
supplement the reduced nitric oxide to attenuate 
myocardial injury associated with ischemia and 
reperfusion i jury. There have been reports that the 
administration f a nitric oxide donor, 15 nitric oxide 
itself, ~6 or L-arginine will ameliorate reperfusion 
injury after normothermic schemia in cats 17 and 
dogs. as A recent study in patients with coronary 
artery disease showed that L-arginine improved ex- 
ercise-induced myocardial perfusion abnormali- 
ties. 19 In contrast, Takeuchi and associates ~4re- 
ported a negative inotropic effect of L-arginine in 
isolated crystalloid-perfused rabbit hearts. This dis- 
crepancy may be due to the difference between 
blood and crystalloid perfusion, although there was 
no ischemia in the Takeuchi experiments. Crystal- 
loid perfusion may induce maximum vasodilation 
from the baseline measurement. 
If nitric oxide release is maintained close to the 
site of injury, it could have cytoprotective effects by 
inhibiting neutrophil aggregation and adherence. 
Recently, nitric oxide has been shown to be an 
endogenous inhibitor of leukocyte chemotaxisy ad- 
herence, 26and activation. 27Because normal endo- 
thelial cells release nitric oxide basally and this nitric 
oxide may prevent leukocytes from adhering to 
endothelial cells, decreased basal release of nitric 
oxide after myocardial ischemia and reperfusion 
may lead to enhanced adherence of leukocytes to 
the coronary endothelium, which could enhance 
leukocyte-induced myocardial injury. 2s 
Increased endothelial production of nitric oxide 
with L-arginine infusion also may be cardioprotec- 
tive through the action of directly quenching super- 
oxide free radicals. Nitric oxide is a primary radical 
species and is inactivated by superoxide radi- 
cals,a1, 12 but nitric oxide also neutralizes superoxide 
radicals.~3 Conditions associated with enhanced pro- 
duction of superoxide have been shown to increase 
neutrophil adherence. Thus administration f nitric 
oxide could prevent endothelial injury resulting 
from superoxide radicals. 
In summary, the current experiments strongly 
suggest asalutary role for endothelial production of 
nitric oxide in recovery after 2 hours of cold car- 
dioplegic ischemia in neonatal amb hearts. The 
beneficial effects of L-arginine after hypothermic 
ischemia and reperfusion seem likely to involve 
enhanced endothelial production of nitric oxide and 
may have clinical application. 
We thank Mark A. Cioffi, MAT, for his technical 
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Discussion 
Dr. Antonio F. Corno (Milan, Italy). We are all aware of 
the importance of reperfusion damage and, more recently, 
reoxygenation damage. We demonstrated with experi- 
mental research that there is a significant correlation 
between the importance of myocardial damage and the 
level of oxygen tension at reperfusion or reoxygenation, 
especially in the neonatal myocardium; furthermore the 
level of calcium in the cardioplegic solution is associated 
with different results. Can you please tell us what oxygen 
tension you used at reperfusion and what the calcium 
content of your cardioplegic solution was? 
Dr. Stanley K. C. Tam (Boston, Mass.). This study has 
shown that L-arginine could be an additive to preserve left 
ventricular function. Do you have any data that will tell us 
whether L-arginine infusion has any detrimental side effect 
in the heart and systemically? 
Dr. Robert A. Guyton (Atlanta, Ca.). You have used a 
crystalloid cardioplegic technique in an isolated heart 
model. Therefore, you have removed from the heart most 
of the endogenous chemicals. Do you think that this 
exaggerates the benefit of adding L-arginine? If you used 
blood cardioplegia or if you used an in vitro heart you 
might have trace levels of L-arginine. 
Dr. Frederick L. Grover (Denver, Colo.). Is it possible 
that what we are seeing here is preconditioning, or some 
form of that? 
Dr. Hiramatsu. Dr. Corno asked about the oxygen 
tension during reperfusion and the calcium content of the 
cardioplegic solution. The gas supplied to the oxygenator 
was 95% oxygen/5% carbon dioxide during the first 20 
minutes of reperfusion, to mimic the circumstances under 
which reperfusion on cardiopulmonary b pass occurs clin- 
ically. When the hemodynamic measurements were made 
at 30 minutes of reperfusion, the gas supplied to the 
oxygenator was 20% oxygen, 75% nitrogen, and 5% 
carbon dioxide. There was no calcium in the cardioplegic 
solution. 
Dr. Tam asked about detrimental systemic effects. We 
have carried out acute experiments in the whole animal, as 
well as in the isolated heart, and have found no detrimen- 
tal side effects. 
Dr. Guyton asked if the results would be the same if 
blood eardioplegia were used or if an in vivo model were 
used. We have not done experiments with blood cardio- 
plegia, but in whole animal experiments carried out by Dr. 
Joseph Forbess in our laboratory, I.-arginine infusions 
during reperfusion improved the recovery of preload 
recruitable stroke work after 2 hours of deep hypothermic 
circulatory arrest. 
Dr. Grover asked if our observations with L-arginine are 
related to preconditioning. As far as we know, precondi- 
tioning is thought o be related either to adenosine or to 
potassium channels, and we do not believe that L-arginine 
has any effects on either adenosine or potassium channels. 
